US-based biotechnology companies Exelixis and MSD have partnered to assess the potential of combining their respective cancer ...

Drug makers Exelixis, Inc. (EXEL) and Merck & Co Inc.(MRK) announced Monday that they have entered into a clinical development ...

Alameda, California Tuesday, October 15, 2024, 14:00 Hrs [IST] ...

Patients in England and Wales with a rare genetic disorder will soon be able to access treatment with MSD's Welireg via the NHS, nearly a year after their counterparts in Scotland. In final draft ...

5, 2024 /CNW/ - Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that it has successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) ...

The companies will also evaluate zanzalintinib with WELIREG (belzutifan), Merck's oral hypoxia-inducible factor-2 alpha (HIF-2) inhibitor, in a phase 1/2 trial and two phase 3 pivotal trials for ...